Jennerex and Transgene have initiated patient enrolment and treatment for a Phase Ib clinical trial to evaluate JX-594 in patients with advanced metastatic, refractory colorectal cancer.
The open-label, intravenous and multi-dose escalation study, which is being conducted at Samsung Cancer Center in Seoul, South Korea, is designed to evaluate the safety, tolerability and maximum tolerated dose of JX-594 for the treatment of refractory colorectal cancer.
The study will enrol up to 15 patients with metastatic colorectal cancer who have failed both oxaliplatin-based and irinotecan-based chemotherapy regimens, and whose tumour is refractory to Erbitux therapy or harbours ras mutations.
The patients will receive bi-weekly intravenous infusions of JX-594 at one of three dose levels.
JX-594 is a proprietary, engineered oncolytic virus that is designed to selectively target and destroy cancer cells.